Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
NCT06207370 · 60 Degrees Pharmaceuticals LLC
Primary completion dateRecorded edit
− Previous value
2025-03-01
+ Updated value
2027-03-01
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Long-Term Safety Study of TafenoquineNCT03320174 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2021-07-13Actual |
| Tafenoquine in Patients With Mild to Moderate COVID-19NCT04533347 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2022-06-30Actual |
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for BabesiosisNCT06207370 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Recruiting | 2027-03-01Estimated |
| B-FREE Chronic Babesiosis StudyNCT06656351 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Recruiting | 2027-02Estimated |
NCT06207370 · 60 Degrees Pharmaceuticals LLC
2025-03-01
2027-03-01
NCT06656351 · 60 Degrees Pharmaceuticals LLC
Not yet recruiting
Recruiting